Hansoh Pharma and Roche Strike Strategic Licensing Deal for Multi-Tumor ADC Portfolio

Hansoh Pharmaceutical (03692.HK) has entered a strategic collaboration and license agreement with Roche covering an ADC portfolio spanning multiple tumor types. Hansoh is eligible for an upfront payment of 400 million US dollars, a 110-million-dollar one-year anniversary payment, and potential milestone payments exceeding 15 billion dollars, and retains tiered royalties on sales.